India Globalization Capital Inc Cash Flow Conversion Efficiency
India Globalization Capital Inc cash flow conversion efficiency. Based on the latest financial reports, India Globalization Capital Inc (IGC) has a cash flow conversion efficiency ratio of -0.258x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.09 Million) by net assets ($8.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of India Globalization Capital Inc (2006–2025)
Cash flow conversion efficiency of India Globalization Capital Inc from 2006 to 2025. This chart illustrates how India Globalization Capital Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for India Globalization Capital Inc for real-time trading data and today's change.
India Globalization Capital Inc Cash Flow Conversion Ratio Explained
India Globalization Capital Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
India Globalization Capital Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of India Globalization Capital Inc ranked by their cash flow conversion efficiency. Also see India Globalization Capital Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AfroCentric Investment Corp
JSE:ACT
|
0.106x |
|
US Global Investors Inc
NASDAQ:GROW
|
0.006x |
|
Nath Bio-Genes (India) Limited
NSE:NATHBIOGEN
|
-0.160x |
|
Brookside Energy Ltd
AU:BRK
|
0.108x |
|
Stakeholder Gold Corp
V:SRC
|
-0.016x |
|
FN REPUBLIC Co. Ltd
KQ:064090
|
0.025x |
|
Galva Technologies Tbk PT
JK:GLVA
|
0.582x |
|
Gromutual Bhd
KLSE:9962
|
-0.015x |
Annual Cash Flow Conversion Efficiency for India Globalization Capital Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of India Globalization Capital Inc from 2006 to 2025. Review India Globalization Capital Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.33 Million | $-4.79 Million | -0.758x | -6.67% |
| 2024-03-31 | $7.32 Million | $-5.20 Million | -0.710x | -50.26% |
| 2023-03-31 | $14.91 Million | $-7.05 Million | -0.473x | -51.32% |
| 2022-03-31 | $23.89 Million | $-7.46 Million | -0.312x | +5.14% |
| 2021-03-31 | $32.80 Million | $-10.80 Million | -0.329x | -0.69% |
| 2020-03-31 | $26.54 Million | $-8.68 Million | -0.327x | -229.65% |
| 2019-03-31 | $33.57 Million | $-3.33 Million | -0.099x | +58.58% |
| 2018-03-31 | $8.06 Million | $-1.93 Million | -0.239x | -26.52% |
| 2017-03-31 | $7.35 Million | $-1.39 Million | -0.189x | -1573.88% |
| 2016-03-31 | $13.95 Million | $-157.70K | -0.011x | +93.55% |
| 2015-03-31 | $14.75 Million | $-2.58 Million | -0.175x | -42.23% |
| 2014-03-31 | $14.15 Million | $-1.74 Million | -0.123x | -1134.88% |
| 2013-03-31 | $14.97 Million | $178.20K | 0.012x | +103.75% |
| 2012-03-31 | $15.82 Million | $-5.02 Million | -0.318x | +12.10% |
| 2011-03-31 | $7.29 Million | $-2.63 Million | -0.361x | -219.70% |
| 2010-03-31 | $26.15 Million | $-2.96 Million | -0.113x | +47.27% |
| 2009-03-31 | $37.86 Million | $-8.11 Million | -0.214x | -2.22% |
| 2008-03-31 | $40.87 Million | $-8.57 Million | -0.210x | -611.92% |
| 2007-03-31 | $52.92 Million | $-1.56 Million | -0.029x | -1451.85% |
| 2006-03-31 | $50.17 Million | $-95.21K | -0.002x | -- |
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more